Erythropoietin in acute renal failure (and acute myocardial infarction)

Abdelrahman M, Sharples EJ, McDonald MC et al (2004) Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22:63–69 Bahlmann FH, DeGroot K, Duckert T, et al (2003) Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64:1648–1652 Calvillo L, Latini R, Kajstura J et al (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802–4806 Chong ZZ, Kang JQ, Maiese K (2002) Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106:2973–2979 Corwin HL, Gettinger A, Pearl RG et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 288:2827–2835 Daemen MA, van 't Veer C, Denecker G et al (1999) Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 104:541–549 Edelstein CL, Shi Y, Schrier RW (1999) Role of caspases in hypoxia-induced necrosis of rat renal proximal tubules. J Am Soc Nephrol 10:1940–1949 Fiordaliso F, Chimenti S, Staszewsky L et al (2005) A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 102:2046–2051 Gong H, Wang W, Kwon TH et al (2004) EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 66:683–695 Heeschen C, Aicher A, Lehmann R et al (2003) Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood 17:37–45 Jaquet K, Krause K, Tawakol-Khodai M et al (2002) Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64:326–333 Kaushal GP, Singh AB, Shah SV (1998) Identification of gene family of caspases in rat kidney and altered expression in ischemia-reperfusion injury. Am J Physiol 274:F587–F595 Liaño F, Junco E, Pascual J et al (1998) The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. The Madrid Acute Renal Failure Study Group. Kidney Int 66:S16–S24 Lieberthal W, Koh JS, Levine JS (1998) Necrosis and apoptosis in acute renal failure. Semin Nephrol 18:505–518 Lieberthal W, Menza SA, Levine JS (1998) Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol 274:F315–F327 Lipsic E, van der Meer P, Henning RH et al (2004) Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44:473–479 Maiese K, Li F, Chong ZZ (2005) New avenues of exploration for erythropoietin. JAMA 293:90–95 Namiuchi S, Kagaya Y, Ohta J et al (2005) High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 45:1406–1412 Park J, Gage BF, Vijayan A (2005) Use of EPO in Critically Ill Patients With Acute Renal Failure Requiring Renal Replacement Therapy. Am J Kidney Dis 46:791–798 Parsa CJ, Matsumoto A, Kim J et al (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999–1007 Patel NS, Sharples EJ, Cuzzocrea S et al (2004) Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 66:983–989 Sasaki R (2003) Pleiotropic functions of erythropoietin. Intern Med 42:142–149 Sharples EJ, Patel N, Brown P et al (2004) Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15:2115–2124 Sheridan AM, Bonventre JV (2001) Pathophysiology of ischemic acute renal failure. Contrib Nephrol 132:7–21 Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37:1775–1780 Spandou E, Tsouchnikas I, Karkavelas G et al (2005) Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 12:240–248 van der Meer P, Lipsic E, Henning RH, et al (2004) Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 6:853–859 van der Meer P, Lipsic E, Henning RH et al (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46:125–133 Vesey DA, Cheung C, Pat B et al (2004) Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19:348–355 Wu H (1999) Inactivation of EPO leads to defects in cardiac morphogenesis. Development 126:3597–3605 Yang CW, Li C, Jung JY et al (2003) Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17:1754–1755